Eli Lilly's weight loss drugs Mounjaro and Zepbound contribute to stock rise amid market growth to $100bn by 2030.

Eli Lilly's stock has risen due to successful weight loss drugs Mounjaro and Zepbound, facing competition from Novo Nordisk. Pfizer, not in the weight loss market, is developing a once-daily oral formulation of danuglipron. Although Pfizer's drug has a long way to go, the market is expected to reach $100bn by 2030, with room for multiple companies to succeed. Lilly's current revenue from its weight loss drugs and lead in commercialization should continue to drive growth.

August 03, 2024
3 Articles